Leonie H A Broersen1,2, Cornelie D Andela1,2, Olaf M Dekkers1,2,3, Alberto M Pereira1,2, Nienke R Biermasz1,2. 1. Department of Medicine, Division of Endocrinology, Leiden University Medical Center, ZA Leiden, The Netherlands. 2. Center for Endocrine Tumors Leiden, Leiden University Medical Center, ZA Leiden, The Netherlands. 3. Department of Clinical Epidemiology, Leiden University Medical Center, ZA Leiden, The Netherlands.
Abstract
BACKGROUND: Cushing syndrome is characterized by glucocorticoid excess, which induces physical and mental symptoms, impairments in functional status and perceived health, resulting in impaired quality of life. Biochemical remission is urgently required; however, quality of life and cognitive function may remain impaired. OBJECTIVE: To perform a systematic review and meta-analysis evaluating changes in health-related quality of life and cognitive functioning in patients with Cushing syndrome after treatment. METHODS: Eight electronic databases were searched in March 2017, and PubMed again in May 2018, to identify potentially relevant articles. Eligible studies were (randomized controlled) trials, cohort studies, and cross-sectional studies assessing quality of life or cognitive functioning in patients treated for Cushing syndrome. Differences were expressed as standardized mean difference and reported with 95% confidence intervals. We compared patients before and after treatment (improvement) and patients after treatment and healthy controls (normalization). RESULTS: We included 47 articles with 2643 patients. Most patients had Cushing disease and were in remission after treatment. Quality of life and cognitive functioning improved after treatment in all studied domains. Compared with a healthy control population, quality of life did not normalize. Cognitive functioning normalized in part, but not all, of the studied domains. CONCLUSIONS: Treatment of Cushing syndrome improves quality of life and cognitive functioning. Because normalization was not achieved in quality of life and in some aspects of cognitive functioning, special and continuous attention should be given to these aspects for patients after treatment. Effective interventions for further improvement and possibly normalization are urgently needed.
BACKGROUND: Cushing syndrome is characterized by glucocorticoid excess, which induces physical and mental symptoms, impairments in functional status and perceived health, resulting in impaired quality of life. Biochemical remission is urgently required; however, quality of life and cognitive function may remain impaired. OBJECTIVE: To perform a systematic review and meta-analysis evaluating changes in health-related quality of life and cognitive functioning in patients with Cushing syndrome after treatment. METHODS: Eight electronic databases were searched in March 2017, and PubMed again in May 2018, to identify potentially relevant articles. Eligible studies were (randomized controlled) trials, cohort studies, and cross-sectional studies assessing quality of life or cognitive functioning in patients treated for Cushing syndrome. Differences were expressed as standardized mean difference and reported with 95% confidence intervals. We compared patients before and after treatment (improvement) and patients after treatment and healthy controls (normalization). RESULTS: We included 47 articles with 2643 patients. Most patients had Cushing disease and were in remission after treatment. Quality of life and cognitive functioning improved after treatment in all studied domains. Compared with a healthy control population, quality of life did not normalize. Cognitive functioning normalized in part, but not all, of the studied domains. CONCLUSIONS: Treatment of Cushing syndrome improves quality of life and cognitive functioning. Because normalization was not achieved in quality of life and in some aspects of cognitive functioning, special and continuous attention should be given to these aspects for patients after treatment. Effective interventions for further improvement and possibly normalization are urgently needed.
Authors: Karol Piotr Sagan; Elżbieta Andrysiak-Mamos; Ernest Tyburski; Leszek Michał Sagan; Anhelli Syrenicz Journal: J Clin Med Date: 2021-04-26 Impact factor: 4.241
Authors: Shaho F Ahmed; Rawa Bapir; Fattah H Fattah; Aras Gh Mahmood; Rawezh Q Salih; Abdulwahid M Salih; Soran H Tahir; Fahmi H Kakamad Journal: Int J Surg Case Rep Date: 2022-04-05
Authors: Jorge Miguel Amaya; Eva M G Viho; Hetty C M Sips; Reshma A Lalai; Isabelle Sahut-Barnola; Typhanie Dumontet; Nathanaëlle Montanier; Alberto M Pereira; Antoine Martinez; Onno C Meijer Journal: J Neuroendocrinol Date: 2022-04-01 Impact factor: 3.870
Authors: Eliza B Geer; Roberto Salvatori; Atanaska Elenkova; Maria Fleseriu; Rosario Pivonello; Przemyslaw Witek; Richard A Feelders; Marie Bex; Stina W Borresen; Soraya Puglisi; Beverly M K Biller; Fredric Cohen; Francesca Pecori Giraldi Journal: Pituitary Date: 2020-11-20 Impact factor: 4.107